TY - JOUR
T1 - Synthesis and characterization of thrombin conjugated γ-Fe 2O3 magnetic nanoparticles for hemostasis
AU - Ziv, Ofra
AU - Lublin-Tennenbaum, Tammy
AU - Margel, Shlomo
PY - 2009/12
Y1 - 2009/12
N2 - Thrombin is the final protease produced in the clotting pathways. Thrombin has been used in the clinic more than six decades for topical hemostasis and wound management. In human plasma the half-life of thrombin is shorter than 15 seconds due to close control by inhibitors. In order to stabilize thrombin, this enzyme was conjugated covalently and physically to γ-Fe2O 3 magnetic nanoparticles. The physical conjugation was accomplished through adsorption of thrombin to BSA coating on the nanoparticles. The coagulant activity of the covalently bound thrombin was significantly lower than that of the physically adsorbed thrombin. Leakage of the physically bound thrombin into PBS containing 4% HSA was negligible. The physical conjugation of thrombin onto the nanoparticles stabilized the thrombin against its major inhibitor antithrombin III and improved its storage stability. At optimal CaCl2 concentration, the clotting time by the bound thrombin is shorter than that of the free enzyme. This novel conjugated thrombin may be an efficient candidate for topical hemostasis and wound healing.
AB - Thrombin is the final protease produced in the clotting pathways. Thrombin has been used in the clinic more than six decades for topical hemostasis and wound management. In human plasma the half-life of thrombin is shorter than 15 seconds due to close control by inhibitors. In order to stabilize thrombin, this enzyme was conjugated covalently and physically to γ-Fe2O 3 magnetic nanoparticles. The physical conjugation was accomplished through adsorption of thrombin to BSA coating on the nanoparticles. The coagulant activity of the covalently bound thrombin was significantly lower than that of the physically adsorbed thrombin. Leakage of the physically bound thrombin into PBS containing 4% HSA was negligible. The physical conjugation of thrombin onto the nanoparticles stabilized the thrombin against its major inhibitor antithrombin III and improved its storage stability. At optimal CaCl2 concentration, the clotting time by the bound thrombin is shorter than that of the free enzyme. This novel conjugated thrombin may be an efficient candidate for topical hemostasis and wound healing.
UR - http://www.scopus.com/inward/record.url?scp=73849113427&partnerID=8YFLogxK
U2 - 10.1002/adem.200990036
DO - 10.1002/adem.200990036
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:73849113427
SN - 1438-1656
VL - 11
SP - B251-B260
JO - Advanced Engineering Materials
JF - Advanced Engineering Materials
IS - 12
ER -